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Identity 
Other names: FAC, FACC, FA3 
HGNC (Hugo): FANCC 
Location: 9q22.32 
Local order: Next to PTCH and XPAC !! 
 




14 exons; spans 80 kb. 
Transcription 
mRNA of 2.3, 3.2, and 4.6 kb (alternative splicing  5', 
variable 3' untranslated region, exon 13 skipping). 
Protein 
Description 
558 amino acids; 63 kDa. 
Expression 
Wide, in particular in the bones; high expression in 
proliferating cells, low in differentiated cells. 
Localisation 
Cytoplasmic (mostly) and nuclear. 
Function 
- FANCA and FANCG form a complex in the 
cytoplasm, through a N-term FANCA (involving the 
nuclear localization signal) - FANCG interaction; 
FANCC join the complex; phosphorylation of FANCA 
would induce its translocation into the nucleus. This 
FA complex translocates into the nucleus, where 
FANCE and FANCF are present; FANCE and FANCF 
join the complex. The FA complex subsequently 
interacts with FANCD2 by monoubiquitination of 
FANCD2 during S phase or following DNA damage. 
Activated (ubiquinated ) FANCD2, downstream in the 
FA pathway, will then interact with other proteins 
involved in DNA repair, possibly BRCA1; after DNA 
repair, FANCD2 return to the non-ubiquinated form.  
- FANCC may have mutlifunctional roles, in addition 
to its involvement in the FA pathway. FANCC binds to 
cdc2 (mitotic cyclin-dependent kinase), STAT1, 
GRP94 (a chaperon protein), NADPH, and a number of 
other proteins; involved in DNA repair and in 
suppressing interferon gamma induced cellular 
apoptosis. 
There are 15 FA genes that make up the FA pathway. 
Among these FANCA, FANCB, FANCC, FANCE, 
FANCF, FANCG, FANCM and FANCL form the core 
complex.  
During G1 phase of cell cycle these proteins are 
localized in the cytoplasm. During S phase or during 
DNA damage FANCA and FANCG at first form a 
complex in the cytoplasm followed by its interaction 
with FANCC.  
Then the complex translocates to the nucleus. In the 
nucleus other FA proteins like FANCE, F, B, M and L 
interact with the complex. They cooperatively bind to 
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form the core complex. FANCL has E3 ubiquitin ligase 
activity.  
The core complex then activates FANCD2 and FANCI 
by monoubiquitination.  
The activated FANCD2-FANCI complex then interact 
with other FA genes like FANCP/SLX4, 
FANCD1/BRCA2, FANCJ/BRIP1 and 
FANCN/PALB2 for efficient DNA repair.  
FANCC helps in accumulation of FANCE and it has 
role in foci formation of MRE11/RAD50/NBS1 
complex in response to intrastrand crosslink inducers.  
FANCC binds to cdc2 (mitotic cyclin-dependent 
kinase), it is necessary for DNA damage-induced G2/M 
checkpoint in vitro and in vivo. 
In response to oxidative DNA damage, FANCC 
prevents premature senescence in hematopoietic stem 
cells.  
It interacts with cytochrome p-450 reductase and 
NADPH during increased production of reactive 
oxygen species (ROS). 
In hematopoietic stem cells it regulates apoptosis, self 
renewal capacity and cell cycle control. It inhibits 
activity of dsRNA dependent protein kinase mediated 
death signaling pathway by interacting with Hsp70.  
FANCC and p53 cooperatively work in apoptosis. It 
has role in suppressing interferon gamma induced 
cellular apoptosis. 
In normal oral epithelium, a gradual increase of 
FANCC protein expression from basal to parabasal 
layer to spinous layer suggesting its role in cellular 
proliferation and differentiation.  
FANCC is important for proper functioning of 
monocytes/macrophages. It suppresses TNFα 
production in mononuclear phagocytes by suppressing 
TLR8 activity.  
FANCC interacts with STAT1, GRP94 (a chaperon 
protein). It has role in telomere attrition and telomere 
recombination. 
Homology 
No known homology. 
Mutations 
Germinal 
Most mutations are found in exon1, intron 4, and exon 
14. 
Implicated in 
Fanconi anaemia (FA) 
Note 
FACC is implicated in the FA complementation group 
C; it represents about 15% of FA cases. 
Disease 
Fanconi anaemia is a chromosome instability 
syndrome/cancer prone disease (at risk of leukaemia). 
 
Prognosis 
- Fanconi anaemia's prognosis is poor; mean survival is 
16 years: patients die of bone marrow failure 
(infections, haemorrhages), leukaemia, or androgen 
therapy related liver tumours.  
- It has recently been shown that significant phenotypic 
differences were found between the various 
complementation groups. FA group C patients had less 
somatic abnormalities. However, there is a certain 
clinical heterogeneity. 
Cytogenetics 
Spontaneous,chromatid/chromosome breaks; increased 
rate of breaks compared to control, when induced by 
breaking agent. 
Hybrid/Mutated gene 
Mutations in exon 4, 13 leading to deletion of exon 9 
were reported in Brazilian Fanconi Anemia patients. 
Oncogenesis 
Fanconi anemia patients are prone to develop head and 
neck, esophageal, gastrointestinal, vulvar and anal 
cancers. 
Frequent deletion and promoter methylation are 
observed in FANCC gene in oral cancer, breast cancer, 
acute leukemia and pancreatic cancer. 
Diabetes and obesity 
Note 
FANCC prevents diabetes and obesity. 
To be noted 
Note 
Apart from its function in DNA damage repair, 
FANCC plays important role in apoptosis, cell cycle, 
differentiation and innate immunity. 
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